Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
BT Zhai, H Tian, J Sun, JB Zou, XF Zhang… - Journal of translational …, 2022 - Springer
Urokinase-type plasminogen activator receptor (uPAR) is an attractive target for the
treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels …
treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels …
Modulation of cellular function by the urokinase receptor signalling: A mechanistic view
D Alfano, P Franco, MP Stoppelli - Frontiers in Cell and …, 2022 - frontiersin.org
Urokinase-type plasminogen activator receptor (uPAR or CD87) is a glycosyl-phosphatidyl-
inositol anchored (GPI) membrane protein. The uPAR primary ligand is the serine protease …
inositol anchored (GPI) membrane protein. The uPAR primary ligand is the serine protease …
Self-assembled chitosan polymer intercalating peptide functionalized gold nanoparticles as nanoprobe for efficient imaging of urokinase plasminogen activator …
Targeting cell surface receptors for specific drug delivery in cancer has garnered lot of
attention. Urokinase plasminogen activator receptor (uPAR), a surface biomarker, is …
attention. Urokinase plasminogen activator receptor (uPAR), a surface biomarker, is …
The acidic domain of the endothelial membrane protein GPIHBP1 stabilizes lipoprotein lipase activity by preventing unfolding of its catalytic domain
S Mysling, KK Kristensen, M Larsson, AP Beigneux… - elife, 2016 - elifesciences.org
GPIHBP1 is a glycolipid-anchored membrane protein of capillary endothelial cells that binds
lipoprotein lipase (LPL) within the interstitial space and shuttles it to the capillary lumen. The …
lipoprotein lipase (LPL) within the interstitial space and shuttles it to the capillary lumen. The …
Graphene nanosheets as an electric mediator for ultrafast sensing of urokinase plasminogen activator receptor-A biomarker of cancer
Fluorine doped tin oxide (FTO) electrochemical immunosensor has been developed for
rapid detection of urokinase type plasminogen activator receptor (uPAR)-a biomarker for …
rapid detection of urokinase type plasminogen activator receptor (uPAR)-a biomarker for …
Polymeric biocompatible iron oxide nanoparticles labeled with peptides for imaging in ovarian cancer
Compared with other nanomaterials, surface-modified iron oxide nanoparticles (IONPs)
have gained attraction for cancer therapy applications due to its low toxicity, and long …
have gained attraction for cancer therapy applications due to its low toxicity, and long …
[HTML][HTML] A concise review on potential cancer biomarkers and advanced manufacturing of smart platform-based biosensors for early-stage cancer diagnostics
Advanced diagnostic technologies for early-stage detection of cancer are essential for
proper management and guided therapeutics to increase chances of survival for patients …
proper management and guided therapeutics to increase chances of survival for patients …
Targeting the urokinase-type plasminogen activator receptor (uPAR) in human diseases with a view to non-invasive imaging and therapeutic intervention
JM Leth, M Ploug - Frontiers in cell and developmental biology, 2021 - frontiersin.org
The interaction between the serine protease urokinase-type plasminogen activator (uPA)
and its glycolipid-anchored receptor (uPAR) focalizes plasminogen activation to cell …
and its glycolipid-anchored receptor (uPAR) focalizes plasminogen activation to cell …
Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners
Highlights•uPAR is a cell surface receptor with diverse functions.•Plasma uPAR level is
typically low and high level is associated with health crisis.•The pleiotropic functions of …
typically low and high level is associated with health crisis.•The pleiotropic functions of …
Structural dynamics-driven discovery of anticancer and antimetastatic effects of diltiazem and glibenclamide targeting urokinase receptor
Y Zhou, M Song, D Xie, S Yan, S Yu, S Xie… - Journal of Medicinal …, 2023 - ACS Publications
Diltiazem and glibenclamide are commonly used hypotensive and antidiabetic drugs. This
study reports the discovery of the potential antitumor and antimetastatic effects of these two …
study reports the discovery of the potential antitumor and antimetastatic effects of these two …